BioPharmSignal logoBioPharmSignal

Biotech News

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma (ATYR)aTyr PharmaEarnings

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as

Open original release

Related news

CLDXCelldex Therapeutics2026-05-07 20:01 EST

Celldex Reports First Quarter Financial Results and Provides Corporate Update

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

BNTXBioNTech2026-05-05 10:45 EST

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BNTXBioNTech2026-04-21 10:45 EST

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

NRIXNurix Therapeutics2026-04-08 10:00 EST

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

View all latest news

aTyr Pharma

aTyr Pharma is a biotechnology company focused on extracellular biology and inflammatory disease. Its story is centered on using novel biology to address serious immune-mediated conditions.

Recent company news

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-05-13 20:01 EST

aTyr Pharma to Participate in Upcoming Investor Conferences

ATYRaTyr Pharma2026-05-11 20:01 EST

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

ATYRaTyr Pharma2026-03-05 21:01 EST

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

ATYRaTyr Pharma2026-02-20 21:01 EST

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
0.49 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States